Clinical Trial Detail

NCT ID NCT03036488
Title Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

triple-receptor negative breast cancer

Therapies

Cyclophosphamide + Epirubicin

Cyclophosphamide + Doxorubicin

Pembrolizumab

Carboplatin + Paclitaxel

Age Groups: adult senior

No variant requirements are available.